Japanese Pediatricians Want 1 Million Children Atop H1N1 Vaccine List
This article was originally published in PharmAsia News
Executive Summary
A Japanese physicians group urged the government to give about 1 million children priority for receiving the H1N1 flu vaccine when it becomes available. The Japan Pediatric Society said the million children are considered high-risk with cancer, kidney failure or asthma or serious physical or mental disabilities. The society said the priority list should include another 5.5 million preschool children and parents of infants under a year old. The pediatricians also urged the government to provide those shots for free instead of charging recipients for each inoculation, as planned. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.